MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma
Open Access
- 1 October 2020
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 10001-10012
Abstract
Purpose: DNA methylation plays an important role in regulating gene expression. Methyl-CpG-binding domain (MBD) proteins recognize and bind to methylated DNA, which mediate gene silencing by the interaction with deacetylases and histone methyltransferases. MBD2 has been reported in various human cancers; however, its clinical implication and potential regulatory role in renal cell carcinoma (RCC) have not been elaborated. Materials and Methods: In the study, we estimated the expression and prognostic value of MBD2 in RCC cell lines and tissues by Western blotting and immunohistochemistry. The associations of MBD2 expression and pathological characters and survival in RCC patients were performed using χ 2 and Kaplan–Meier survival analysis, respectively. Univariate and multivariable Cox regression analyses suggested the independent predictors in RCC prognosis. The functional role of MBD2 in RCC progression was assessed by in vitro cell experiments. In addition, we identified the MBD2-mediated alterations of protein-related proliferation and EMT markers in RCC cells after MBD2 overexpression and knockdown. Results: We found that the protein levels of MBD2 were upregulated in RCC cells and tissues. High MBD2 expression was related to TNM stage and predicted poorer survival in RCC. Enforced expression of MBD2 significantly promoted the proliferation, cycle progress, invasion and migration of RCC cells in vitro. However, downregulating MBD2 remarkably weakened the above cell functions. Mechanistically, the promotive effect of MBD2 overexpression may be regulated by its effects onp21, p53 and Cyclin D1 expression and EMT process. Conclusion: These results indicated that MBD2confers an oncogenic function in the malignant progression of RCC. MBD2 could be served as a meaningful prognostic biomarker and a latent therapeutic target in RCC patients.Keywords
This publication has 45 references indexed in Scilit:
- Methylated DNA Binding Domain Protein 2 (MBD2) Coordinately Silences Gene Expression through Activation of the MicroRNA hsa-mir-496 Promoter in Breast Cancer Cell LinePLOS ONE, 2013
- Overexpression of MBD2 in Glioblastoma Maintains Epigenetic Silencing and Inhibits the Antiangiogenic Function of the Tumor Suppressor Gene BAI1Cancer Research, 2011
- The Roles of the Methyl-CpG Binding Proteins in CancerGenes & Cancer, 2011
- miR-373 Negatively Regulates Methyl-CpG-Binding Domain Protein 2 (MBD2) in Hilar CholangiocarcinomaDigestive Diseases and Sciences, 2010
- CpG island promoter methylation and silencing of 14-3-3σ gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2Oncogene, 2006
- Role of MBD2 in gene regulation and tumorigenesisBiochemical Society Transactions, 2005
- Deficiency of Mbd2 suppresses intestinal tumorigenesisNature Genetics, 2003
- Methyl-CpG Binding Domain Protein 2 Represses Transcription from Hypermethylated π-Class Glutathione S-Transferase Gene Promoters in Hepatocellular Carcinoma CellsJournal of Biological Chemistry, 2002
- Reduced mRNA Expression of the DNA Demethylase, MBD2, in Human Colorectal and Stomach CancersBiochemical and Biophysical Research Communications, 1999
- Eosinophilic granulomatous dacryoadenitis causing bilateral keratoconjunctivitis sicca in a horseEquine Veterinary Journal, 1989